Paris - Hôpital Cochin

The cardiology service at Hôpital Cochin is evaluating innovative catheter‑based strategies to improve outcomes for patients with coronary artery disease and high bleeding risk. Trials aim to compare newer device technologies and shorten antiplatelet therapy.

• Percutaneous coronary intervention with drug‑coated balloon versus drug‑eluting stent
• Management of stable coronary artery disease in anticoagulated patients
• Assessment of bleeding risk reduction strategies

These studies support personalized interventional approaches and may influence future guidelines for cardiac care in France.

Research on non‑seminomatous germ‑cell tumors focuses on young adults with poor‑prognosis disease, testing personalized marker‑driven treatment plans to enhance survival.

• Prospective validation of early tumor‑marker kinetics
• Tailored chemotherapy regimens for disseminated germ‑cell disease
• Safety monitoring of personalized protocols

The program, conducted at the Cochin oncology‑urology interface, seeks to set new standards for male reproductive cancer management.

A broad oncology portfolio addresses solid tumours such as advanced non‑small cell lung cancer, metastatic kidney cancer, and sarcomas, with trials investigating immune checkpoint inhibitors, targeted agents, and molecularly guided therapies.

• Pembrolizumab plus cabozantinib in advanced sarcoma subtypes
• Adjuvant chemotherapy guided by a 14‑gene prognostic assay for resected NSCLC
• Nivolumab‑based combinations stratified by renal cell carcinoma molecular groups
• Oral fecal microbiotherapy with cemiplimab for checkpoint‑inhibitor‑resistant NSCLC

These investigations aim to improve response rates and personalize treatment across diverse cancer types.

Clinical work in lung disease includes studies on metastatic non‑small cell lung cancer and the prevention of second primary cancers after curative therapy, evaluating immunotherapy and vaccine strategies.

• Efficacy of pembrolizumab‑cabozantinib in advanced NSCLC
• Dostarlimab as adjuvant therapy to reduce second primary cancer risk
• Biomarker‑driven adjuvant trials for early‑stage NSCLC

The site’s multidisciplinary team integrates pulmonology and oncology to accelerate advances in lung health.

Investigations into moderate‑to‑severe hidradenitis suppurativa test novel oral agents to determine optimal dosing and safety, aiming to expand therapeutic options for this chronic inflammatory condition.

• Dose‑finding study of LAD191
• Safety assessment of multiple dosing regimens
• Evaluation of disease‑control rate at 12 weeks

Outcomes may lead to new approved medications for patients with refractory skin disease.

Additional projects explore secondary prevention of HPV-related high‑grade squamous intra‑epithelial lesions using a nonavalent vaccine, targeting gynecological and anal sites to lower recurrence risk.

• HPV vaccination as secondary prevention
• Assessment of vaccine efficacy in cured HSIL patients
• Long‑term monitoring for second primary lesions

These efforts complement the site’s broader commitment to cancer prevention and public health.